Akso Health

On the surface, the FY2026 balance sheet looks asset‑heavy with 189.6 million dollars of assets, driven by 175.7 million dollars of advances for capital expenditures.

Management states all advances were refunded in June 2026, implying pro forma cash near 175.8 million dollars post period‑end against total liabilities of 8.7 million dollars and only modest loans (0.35 million dollars third‑party, 2.0 million dollars due to related party).

However, FY2026 operating cash flow was negative 12.8 million dollars and the auditor cited going‑concern uncertainty. Financial strength is thus mixed: large pro forma cash, low financial debt, but cash burn, impairments, and execution risk.